Abstract
Cholangiocarcinoma (CCA) is an aggressive malignancy originating from the neoplastic transformation of the epithelial cells of the bile ducts, both intrahepatic (iCCA) and extrahepatic (eCCA), and among the fastest growing cancers in the United states. Therapeutic options for CCA patients at advanced stages are limited and palliative chemotherapy remains the main treatment option. Over the past decade, the application of next-generation sequencing has significantly impacted the management of CCA where clinically-relevant subgroups have been identified based on the recurrence of specific structural aberrations (i.e. FGFR2 fusions, IDH1 mutations) with important differences according to the anatomical site. These efforts have increased the molecular understanding of this disease and ultimately suggested that iCCA and eCCA may represent distinct entities. Thereby, increasing efforts have tried to generate molecular classifications specific for each subtype, although initial studies analyzed CCA samples regardless of their anatomic site of origin. We will review current knowledge of the molecular landscape and immunogenomic classifications proposed to date for iCCA and eCCA.
Citation Format: Daniela Sia. Molecular classes and landscape of drivers of intrahepatic and extrahepatic cholangiocarcinoma [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl):Abstract nr IA22.
RSS Feeds